Abstract |
Herein, we reported our experience in colchicine-resistant familial Mediterranean fever (FMF) patients who are treated with anti-interleukin-1 (IL-1) drugs. A retrospective review of medical records of anti-IL-1 recipients was performed. The main clinical characteristics of these patients and the evolution after anti-IL-1 were recorded. There were 20 patients (11 male [M] and 9 female [F]). Despite regular colchicine treatment, median number of attacks per month and per year was 1 (1-4) and 12 (4-50), respectively. Twelve patients were receiving anakinra, and eight patients were treated with canakinumab. The number of monthly and yearly attacks after IL-1 treatment was significantly decreased after the biologic agent (p < 0.05). One patient did not respond to the treatment, and one patient developed serious infection during anti-IL-1. We also observed a significant decrease in proteinuria in the amyloidosis complicated FMF patients. Anti-IL-1 targeting drugs seem safe and effective therapies in colchicine-resistant FMF.
|
Authors | Pinar Cetin, Ismail Sari, Betul Sozeri, Ozlem Cam, Merih Birlik, Nurullah Akkoc, Fatos Onen, Servet Akar |
Journal | Inflammation
(Inflammation)
Vol. 38
Issue 1
Pg. 27-31
(Feb 2015)
ISSN: 1573-2576 [Electronic] United States |
PMID | 25139580
(Publication Type: Journal Article)
|
Chemical References |
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Interleukin 1 Receptor Antagonist Protein
- Interleukin-1
- canakinumab
|
Topics |
- Adolescent
- Adult
- Antibodies, Monoclonal
(administration & dosage)
- Antibodies, Monoclonal, Humanized
- Drug Delivery Systems
(methods)
- Familial Mediterranean Fever
(diagnosis, drug therapy, metabolism)
- Female
- Humans
- Interleukin 1 Receptor Antagonist Protein
(administration & dosage)
- Interleukin-1
(antagonists & inhibitors, metabolism)
- Male
- Middle Aged
- Retrospective Studies
- Treatment Outcome
- Young Adult
|